A. Lockhart

发表

FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.

A. Lockhart, K. Lim, R. Suresh, 2020, JAMA oncology.

Folate Receptor Alpha Targeted 89Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple Negative Breast Cancer.

J. Stec, Shunqiang Li, R. Laforest, 2019, Molecular pharmaceutics.

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

J. Lacy, S. Park, Y. Bang, 2020, The Lancet. Oncology.

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

Kathryn J Fowler, M. Yano, A. Lockhart, 2016, The Lancet. Oncology.